@chonyalbertmd.bsky.social; Director LVAD/MCS RWJUH NJ. Advanced Heart Failure and Transplant Cardiologist. Penn med and Cleveland Clinic card alumnus.
What an excellent and engaging set of debates on MRA use in the HFrEF and HFpEF populations! My general takeaway is to not be afraid to use MRA even in more advanced CKD while of course monitoring for hyperK. Great to recap emerging data for non steroidal MRAs! #Acc26
Interesting insights from the STEMI-DTU trial evaluating strategy of upfront LV unloading with Impella CP device with 30 min delay prior to revascularization in patients without cardiogenic shock. No statistically significance between LV unloading vs usual care. #ACC2026
Intriguing data from MAPLE hcm presented at @HFSA - discordant CPET parameters for aficamten vs metoprolol with aficamten besting metoprolol in every CPET metric #HFSA2025